Chugai and Novartis Pharma to Terminate Co-Marketing Agreement of Aromatase Inhibitor "Femara® Tablets 2.5 mg," a Treatment for Breast Cancer after Menopause

TOKYO, January 6, 2016 - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Chugai and Novartis Pharma K.K. have agreed to terminate the agreement regarding co-marketing of aromatase inhibitor "Femara® tablets 2.5 mg" (generic name: letrozole, hereafter Femara®), a treatment for breast cancer after menopause in Japan, as of January 31, 2016.
Novartis Pharma will be solely responsible for the distribution and commercialization of Femara® in Japan from February 1, 2016.

Chugai and Novartis Pharma will cooperate to accomplish a smooth transition. During the transition period, both companies will maintain the same level of product supply and adequate commercial activities to satisfy any medical needs.

About Femara® Tablets 2.5 mg

Generic Name: Letrozole
Brand Name: Femara® Tablets 2.5 mg
Approval Date: January 23, 2006
Launch Date: May 11, 2006
Indication: Breast cancer after menopause
Dosage and administration: The usual adult dosage is 2.5 mg administered orally once daily.
Drug Price: JPY 674.1/Tablet
Manufacturer & Distributor: Novartis Pharma K.K.
Distribution and commercialization: Novartis Pharma K.K. (on or after February 1, 2016)
Contact:
For Media
Chugai Pharmaceutical Co., Ltd
Media Relations Group, Corporate Communications Dept.,
Koki Harada
Tel: +81-3-3273-0881
E-mail: [email protected]

For Investors
Chugai Pharmaceutical Co., Ltd
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: [email protected]

Suggested Articles

Fujifilm Diosynth Biotechnologies last year committed 10 billion yen toward its manufacturing operations. It has now kicked off one of those projects.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

With a new target date approaching for its competitor to Lantus, the FDA has again given Biocon’s insulin manufacturing plant in Malaysia a once over.